Details of Drug

Drug General Information (ID: D0907)
Drug Name	Letrozole
Drug Type	Small molecule
Drug Synonymous	Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile Click to Show/Hide
Disease Class	2C60-2C6Y: Breast cancer
Therapeutic Class	Antineoplastics
Structure
Structure	3D Structure		2D Structure
Formula	C17H11N5
InChI	1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
InChIKey	HPJKCIUCZWXJDR-UHFFFAOYSA-N
Canonical SMILES	C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
External Link
	Pubchem ID	3902
	CAS Number	112809-51-5
	CHEBI ID	6413
	TTD ID	D0C1WH
	INTEDE ID	DR0929

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM017 CYP450 enzyme inhibition BM022 CYP450 enzyme induction BM024 Competitive inhibition of metabolic enzyme BM044 Additive myelosuppressive effects BM047 Additive thrombogenic effects BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Letrozole
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 39
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0345		Citalopram	C20H21FN2O	2771	Major		Inter Info	[1], [2], [3]
D0100		Aprepitant	C23H21F7N4O3	135413536	Moderate		Inter Info	[20], [21]
D0356		Clobazam	C16H13ClN2O2	2789	Moderate		Inter Info	[26]
D0364		Clopidogrel	C16H16ClNO2S	60606	Moderate		Inter Info	[27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45]
D0386		Conivaptan	C32H26N4O2	151171	Moderate		Inter Info	[46]
D0002		Abametapir (topical)	C12H12N2	15664	Moderate		Inter Info	[51]
D0192		Boceprevir	C27H45N5O5	10324367	Moderate		Inter Info	[53]
D0302		Ceritinib	C28H36ClN5O3S	57379345	Moderate		Inter Info	[56], [22], [57]
D0336		Cilostazol	C20H27N5O2	2754	Moderate		Inter Info	[58], [59], [60], [61], [62], [63], [64], [65], [66]
D0426		Darunavir	C27H37N3O7S	213039	Moderate		Inter Info	[68]
D0428		Dasatinib	C22H26ClN7O2S	3062316	Moderate		Inter Info	[69]
D0432		Deferasirox	C21H15N3O4	214348	Moderate		Inter Info	[70], [71]
D0534		Dronedarone	C31H44N2O5S	208898	Moderate		Inter Info	[72]
D0543		Duvelisib	C22H17ClN6O	50905713	Moderate		Inter Info	[73]
D0599		Escitalopram	C20H21FN2O	146570	Moderate		Inter Info	[77], [56], [22], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87]
D0638		Fedratinib	C27H36N6O3S	16722836	Moderate		Inter Info	[22], [89]
D0665		Flibanserin	C20H21F3N4O	6918248	Moderate		Inter Info	[90]
D0693		Fosaprepitant	C23H22F7N4O6P	135413538	Moderate		Inter Info	[20], [21]
D0699		Fostamatinib	C23H26FN6O9P	11671467	Moderate		Inter Info	[93]
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[94]
D0852		Isavuconazonium	C35H35F2N8O5S+	6918606	Moderate		Inter Info	[22], [95]
D0869		Ivacaftor	C24H28N2O3	16220172	Moderate		Inter Info	[96]
D0894		Lapatinib	C29H26ClFN4O4S	208908	Moderate		Inter Info	[97]
D0896		Larotrectinib	C21H22F2N6O2	46188928	Moderate		Inter Info	[56], [22], [98]
D0899		Lefamulin	C28H45NO5S	25185057	Moderate		Inter Info	[99]
D0906		Letermovir	C29H28F4N4O4	45138674	Moderate		Inter Info	[100]
D0946		Lonafarnib	C27H31Br2ClN4O2	148195	Moderate		Inter Info	[101]
D1136		Nilotinib	C28H22F3N7O	644241	Moderate		Inter Info	[103]
D1299		Pirfenidone	C12H11NO	40632	Moderate		Inter Info	[22], [105], [106]
D1398		Ribociclib	C23H30N8O	44631912	Moderate		Inter Info	[108], [109], [110], [111], [112], [113], [114], [115], [116]
D1432		Rucaparib	C19H18FN3O	9931954	Moderate		Inter Info	[57]
D1459		Selpercatinib	C29H31N7O3	134436906	Moderate		Inter Info	[22], [120]
D1541		Telaprevir	C36H53N7O6	3010818	Moderate		Inter Info	[125]
D1660		Tucatinib	C26H24N8O2	51039094	Moderate		Inter Info	[129]
D1544		Telithromycin	C43H65N5O10	3002190	Moderate		Inter Info	[135], [136]
D0439		Delavirdine	C22H28N6O3S	5625	Minor		Inter Info	[137], [138], [139], [140], [141], [142]
D0208		Brivaracetam	C11H20N2O2	9837243	Minor		Inter Info	[22], [148]
D0248		Cannabidiol	C21H30O2	644019	Minor		Inter Info	[22], [149]
D1265		Phenobarbital	C12H12N2O3	4763	Minor		Inter Info	[150]
	CYP450 enzyme induction					Drug Num: 23
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0178		Bexarotene	C24H28O2	82146	Moderate		Inter Info	[22], [23], [24]
D0194		Bosentan	C27H29N5O6S	104865	Moderate		Inter Info	[25]
D0554		Efavirenz	C14H9ClF3NO2	64139	Moderate		Inter Info	[50]
D0095		Apalutamide	C21H15F4N5O2S	24872560	Moderate		Inter Info	[22], [52]
D0204		Brigatinib	C29H39ClN7O2P	68165256	Moderate		Inter Info	[54]
D0300		Cenobamate	C10H10ClN5O2	11962412	Moderate		Inter Info	[55]
D0406		Dabrafenib	C23H20F3N5O2S2	44462760	Moderate		Inter Info	[22], [67]
D0545		Echinacea	NA	NA	Moderate		Inter Info	[56], [74]
D0578		Enzalutamide	C21H16F4N4O2S	15951529	Moderate		Inter Info	[75], [56], [22], [76]
D0628		Etravirine	C20H15BrN6O	193962	Moderate		Inter Info	[88]
D0953		Lorlatinib	C21H19FN6O2	71731823	Moderate		Inter Info	[102]
D1302		Pitolisant	C17H26ClNO	9948102	Moderate		Inter Info	[22], [107]
D1401		Rifapentine	C47H64N4O12	135403821	Moderate		Inter Info	[117], [118]
D1433		Rufinamide	C10H8F2N4O	129228	Moderate		Inter Info	[22], [119]
D1493		Somapacitan	C54H95N13O20S2	129894493	Moderate		Inter Info	[56], [22], [121]
D1495		Somatrem	C43H72N14O14	5487805	Moderate		Inter Info	[56], [22], [122], [121]
D1502		St. John's Wort	NA	NA	Moderate		Inter Info	[123], [124]
D1546		Telotristat ethyl	C27H26ClF3N6O3	25181577	Moderate		Inter Info	[22], [126]
D1128		Nevirapine	C15H14N4O	4463	Moderate		Inter Info	[56], [22], [130], [131]
D1198		Oxcarbazepine	C15H12N2O2	34312	Moderate		Inter Info	[132], [133], [134]
D1494		Somatotropin	NA	NA	Moderate		Inter Info	[56], [22], [121]
D0106		Armodafinil	C15H15NO2S	9690109	Minor		Inter Info	[143], [144], [145], [146], [147]
D1081		Modafinil	C15H15NO2S	4236	Minor		Inter Info	[143], [144], [145], [146], [147]
	Competitive inhibition of metabolic enzyme					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0696		Fosnetupitant	C31H35F6N4O5P	71544786	Moderate		Inter Info	[56], [91], [92]
D1127		Netupitant	C30H32F6N4O	6451149	Moderate		Inter Info	[56], [91], [92]
D1549		Temsirolimus	C56H87NO16	6918289	Moderate		Inter Info	[127], [128]
D1476		Sirolimus	C51H79NO13	5284616	Moderate		Inter Info	[127], [128]
D1526		Tacrolimus	C44H69NO12	445643	Moderate		Inter Info	[127], [128]
Pharmacodynamic additive effects
	Additive myelosuppressive effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1174		Omacetaxine mepesuccinate	C29H39NO9	285033	Moderate		Inter Info	[104]
	Additive thrombogenic effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Major		Inter Info	[4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]
Pharmacodynamic antagonistic effects
	Attenuated pharmacological effects (Unspecific)					Drug Num: 12
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0387		Conjugated estrogens	C18H21NaO5S	45357473	Moderate		Inter Info	[47], [48], [49]
D0388		Conjugated estrogens (topical)	C18H21NaO5S	45357473	Moderate		Inter Info	[47], [48], [49]
D0484		Dienestrol (topical)	C18H18O2	667476	Moderate		Inter Info	[47], [48], [49]
D0487		Diethylstilbestrol	C18H20O2	448537	Moderate		Inter Info	[47], [48], [49]
D0609		Estrone	C18H22O2	5870	Moderate		Inter Info	[47], [48], [49]
D0619		Ethinylestradiol	C20H24O2	5991	Moderate		Inter Info	[47], [48], [49]
D0605		Esterified estrogens	NA	NA	Moderate		Inter Info	[47], [48], [49]
D0608		Estramustine	C23H31Cl2NO3	259331	Moderate		Inter Info	[47], [48], [49]
D0610		Estrone sulfate	C18H22O5S	3001028	Moderate		Inter Info	[47], [48], [49]
D0611		Estrone sulfate (topical)	C18H22O5S	3001028	Moderate		Inter Info	[47], [48], [49]
D1011		Mestranol	C21H26O2	6291	Moderate		Inter Info	[47], [48], [49]
D1370		Quinestrol	C25H32O2	9046	Moderate		Inter Info	[47], [48], [49]

References
1	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).".
2	Priskorn M, Larsen F, Segonzac A, Moulin M "Pharmacokinetic interaction study of citalopram and cimetidine in healhy subjects." Eur J Clin Pharmacol 52 (1997): 241-2. [PMID: 9218934]
3	Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
4	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
5	Bennett CL, Schumock GT, Desai AA, et al "Thalidomide-associated deep vein thrombosis and pulmonary embolism." Am J Med 113 (2002): 603-6. [PMID: 12459408]
6	Cavo M, Zamagni E, Cellini C, et al. "Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy." Blood 100 (2002): 2272-3. [PMID: 12229885]
7	Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A "Thalidomide and venous thrombosis." Ann Intern Med 136 (2002): 711. [PMID: 11992318]
8	Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
9	Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304. [PMID: 12805330]
10	Lee CK, Barlogie B, Munshi N, et al "DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma." J Clin Oncol 21 (2003): 2732-9. [PMID: 12860952]
11	Osman K, Comenzo R, Rajkumar SV "Deep venous thrombosis and thalidomide therapy for multiple myeloma." N Engl J Med 344 (2001): 1951-2. [PMID: 11419443]
12	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
13	Rajkumar SV, Hayman S, Gertz MA, et al. "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma." J Clin Oncol 20 (2002): 4319-23. [PMID: 12409330]
14	Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J "Thromboembolic events during treatment with thalidomide." Blood 99 (2002): 4247-8. [PMID: 12043695]
15	Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma." J Clin Oncol 21 (2003): 16-9. [PMID: 12506164]
16	Zangari M, Anaissie E, Barlogie B, et al "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy." Blood 98 (2001): 1614-5. [PMID: 11520815]
17	Zangari M, Barlogie B, Anaissie E, et al "Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation." Br J Haematol 126 (2004): 715-21. [PMID: 15327525]
18	Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71. [PMID: 12149193]
19	Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM "A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma." Cancer 95 (2002): 1629-36. [PMID: 12365009]
20	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
21	Product Information. Emend for Injection (fosaprepitant). Merck & Company Inc, West Point, PA.
22	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
23	Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.
24	Wakelee HA, Takimoto CH, Lopez-Anaya A, et al. "The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer." Cancer Chemother Pharmacol 69 (2012): 563-71. [PMID: 22057855]
25	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
26	Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
27	Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
28	Frere C, Cuisset T, Morange PE, et al. "Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome." Am J Cardiol 101 (2008): 1088-1093. [PMID: 18394438]
29	Gilard M, Arnaud B, Cornily JC, et al "Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study." J Am Coll Cardiol 51 (2008): 256-60. [PMID: 18206732]
30	Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J "Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin." J Thromb Haemost 4 (2006): 2508-9. [PMID: 16898956]
31	Hulot JS, Bura A, Villard E, et al. "Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects." Blood (2006):. [PMID: 16772608]
32	Juurlink DN, Gomes T, Ko DT, et al "A population-based study of the drug interaction between proton pump inhibitors and clopidogrel." CMAJ 180 (2009): 713-8. [PMID: 19176635]
33	Lau WC, Gurbel PA "The drug-drug interaction between proton pump inhibitors and clopidogrel." CMAJ 180 (2009): 699-700. [PMID: 19332744]
34	Li XQ, Andersson TB, Ahlstrom M, Weidolf L "Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities." Drug Metab Dispos 32 (2004): 821-7. [PMID: 15258107]
35	Mega JL, Close SL, Wiviott SD, et al. "Cytochrome p-450 polymorphisms and response to clopidogrel." N Engl J Med 360 (2009): 354-62. [PMID: 19106084]
36	Moayyedi P, Sadowski DC "Proton pump inhibitors and clopidogrel -- hazardous drug interaction or hazardous interpretation of data?" Can J Gastroenterol 23 (2009): 251-2. [PMID: 19373416]
37	Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T "Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions." Br J Clin Pharmacol 49 (2000): 244-53. [PMID: 10718780]
38	Pezalla E, Day D, Pulliadath I "Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors." J Am Coll Cardiol 52 (2008): 1038-9. [PMID: 18786491]
39	Product Information. Cordarone (amiodarone). Wyeth-Ayerst Laboratories, Philadelphia, PA.
40	Product Information. Kapidex (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
41	Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.
42	Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B "Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel." Am Heart J 157 (2009): 148.e1-5. [PMID: 19081411]
43	Simon T, Verstuyft C, Mary-Krause M, et al "Genetic determinants of response to clopidogrel and cardiovascular events." N Engl J Med 360 (2009): 363-75. [PMID: 19106083]
44	Small DS, Farid NA, Payne CD, et al. "Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel." J Clin Pharmacol 48 (2008): 475-84. [PMID: 18303127]
45	Varenhorst C, Janes S, Erlinge D, et al "Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease." Eur Heart J 30 (2009): 1744-52. [PMID: 19429918]
46	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
47	Product Information. Aromasin (exemestane) Pharmacia &amp Upjohn, Kalamazoo, MI.
48	Product Information. Femara (letrozole). Novartis Pharmaceuticals, East Hanover, NJ.
49	Product Information. Arimidex (anastrozole). Zeneca Pharmaceuticals, Wilmington, DE.
50	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
51	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
52	Product Information. Erleada (apalutamide). Janssen Biotech, Inc., Horsham, PA, PA.
53	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
54	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
55	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
56	Cerner Multum, Inc. "Australian Product Information.".
57	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
58	Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
59	Herrlin K, Segerdahl M, Gustafsson LL, Kalso E "Methadone, ciprofloxacin, and adverse drug reactions." Lancet 356 (2000): 2069-70. [PMID: 11145498]
60	McLellan RA, Drobitch RK, Monshouwer M, Renton KW "Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human." Drug Metab Dispos 24 (1996): 1134-8. [PMID: 8894516]
61	Product Information. Pletal (cilostazol). Otsuka American Pharmaceuticals, Rockville, MD.
62	Sawant RD "Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin." Can J Clin Pharmacol 16 (2009): e78-9. [PMID: 19151423]
63	Shahzadi A, Javed I, Aslam B, et al. "Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers." Pak J Pharm Sci 24 (2011): 63-8. [PMID: 21190921]
64	Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M "Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers." Biopharm Drug Dispos 32 (2011): 168-74. [PMID: 21360715]
65	Suri A, Bramer SL "Effect of omeprazole on the metabolism of cilostazol." Clin Pharmacokinet 37 (1999): 53-9. [PMID: 10702887]
66	Suri A, Forbes WP, Bramer SL "Effects of CYP3A inhibition on the metabolism of cilostazol." Clin Pharmacokinet 37 (1999): 61-8. [PMID: 10702888]
67	Product Information. Tafinlar (dabrafenib). GlaxoSmithKline, Research Triangle Park, NC.
68	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
69	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
70	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
71	Skerjanec A, Wang J, Maren K, Rojkjaer L "Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers." J Clin Pharmacol 50 (2010): 205-13. [PMID: 19940232]
72	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
73	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
74	Gorski JC, Huang SM, Pinto A, et al. "The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo." Clin Pharmacol Ther 75 (2004): 89-100. [PMID: 14749695]
75	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
76	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
77	Canadian Pharmacists Association.
78	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
79	Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2. [PMID: 7476638]
80	Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78. [PMID: 8993077]
81	Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21. [PMID: 9169967]
82	Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6. [PMID: 8909274]
83	Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763. [PMID: 9330840]
84	Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8. [PMID: 8257462]
85	Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9. [PMID: 8681579]
86	Product Information. Lexapro (escitalopram). Forest Pharmaceuticals, St. Louis, MO.
87	Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13. [PMID: 2035713]
88	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
89	Product Information. Inrebic (fedratinib). Celgene Corporation, Summit, NJ.
90	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
91	Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
92	Product Information. Akynzeo for Injection (fosnetupitant-palonosetron). Helsinn Therapeutics Inc, Woodbridge Township, NJ.
93	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
94	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
95	Product Information. Cresemba (isavuconazonium). Astellas Pharma US, Inc, Deerfield, IL.
96	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
97	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
98	Product Information. Vitrakvi (larotrectinib). Bayer Pharmaceutical Inc, West Haven, CT.
99	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
100	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
101	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
102	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
103	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
104	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
105	Product Information. Esbriet (pirfenidone). Intermune Inc, Brisbane, CA.
106	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
107	Product Information. Wakix (pitolisant). Harmony Biosciences, LLC, Plymouth Meeting, PA.
108	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
109	Kane GC, Lipsky JJ "Drug-grapefruit juice interactions." Mayo Clin Proc 75 (2000): 933-42. [PMID: 10994829]
110	Katoh M, Nakajima M, Yamazaki H, Yokoi T "Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport." Eur J Pharm Sci 12 (2001): 505-13. [PMID: 11231118]
111	Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA "Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability." Am J Trop Med Hyg 66 (2002): 260-3. [PMID: 12139218]
112	Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
113	Rawden HC, Kokwaro GO, Ward SA, Edwards G "Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes." Br J Clin Pharmacol 49 (2000): 313-22. [PMID: 10759686]
114	Trivier JM, Libersa C, Belloc C, Lhermitte M "Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report)." Life Sci 52 (1993): pl91-6. [PMID: 8445979]
115	Yu DK "The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions." J Clin Pharmacol 39 (1999): 1203-11. [PMID: 10586385]
116	Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R "Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions." Biochem Pharmacol 45 (1993): 853-61. [PMID: 8452560]
117	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
118	Thijssen HH, Flin ois JP, Beaune PH "Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes." Drug Metab Dispos 28 (2000): 1284-90. [PMID: 11038154]
119	Product Information. Banzel (rufinamide). Eisai Inc, Teaneck, NJ.
120	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
121	Product Information. Zorbtive (somatropin). Serono Laboratories Inc, Rockland, MA.
122	Product Information. Humatrope (somatropin). Lilly, Eli and Company, Indianapolis, IN.
123	Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH "St John's Wort: Effect on CYP3A4 activity." Clin Pharmacol Ther 67 (2000): 451-7. [PMID: 10824623]
124	Sparreboom A, Cox MC, Acharya MR, Figg WD "Herbal remedies in the United States: potential adverse interactions with anticancer agents." J Clin Oncol 22 (2004): 2489-503. [PMID: 15197212]
125	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
126	Product Information. Xermelo (telotristat ethyl). Lexicon Pharmaceuticals, Inc., The Woodlands, TX.
127	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
128	Product Information. Rapamune (sirolimus) Wyeth-Ayerst Laboratories, Philadelphia, PA.
129	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
130	Product Information. Viramune (nevirapine). Boehringer-Ingelheim, Ridgefield, CT.
131	Product Information. Viramune XR (nevirapine). Boehringer Ingelheim, Ridgefield, CT.
132	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
133	Rosche J, Froscher W, Abendroth D, Liebel J "Possible oxcarbazepine interaction with cyclosporine serum levels: A single case study." Clin Neuropharmacol 24 (2001): 113-6. [PMID: 11307049]
134	Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC "Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine." Ther Drug Monit 15 (1993): 39-42. [PMID: 8451779]
135	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
136	European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products "European Public Assessment Report Ketek (telithromycin) (Rev. 2) ".
137	Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
138	Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL "Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test." Clin Pharmacol Ther 61 (1997): 531-43. [PMID: 9164415]
139	Fichtenbaum CJ, Gerber JG "Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection." Clin Pharmacokinet 41 (2002): 1195-211. [PMID: 12405866]
140	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
141	vonMoltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, Harmatz JS, Shader RI "Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors." J Clin Pharmacol 41 (2001): 85-91. [PMID: 11225565]
142	Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, Wang X "Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A." J Pharmacol Exp Ther 287 (1998): 381-8. [PMID: 9765359]
143	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
144	Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
145	Product Information. Provigil (modafinil). Cephalon, Inc, West Chester, PA.
146	Robertson P Jr, Hellriegel ET, Arora S, Nelson M "Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers." Clin Pharmacol Ther 71 (2002): 46-56. [PMID: 11823757]
147	Robertson P, Decory HH, Madan A, Parkinson A "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil." Drug Metab Dispos 28 (2000): 664-71. [PMID: 10820139]
148	Product Information. Briviact (brivaracetam). UCB Pharma Inc, Smyrna, GA.
149	Product Information. Epidiolex (cannabidiol). Greenwich Biosciences Inc, Carlsbad, CA.
150	Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence